Our bicyclic imidazazole nuleophilic catalyst (J. Am. Chem. Soc., 2010, 132, 15939-15941.) has been used and modified by Merck to prepare a chiral phosphoramidate, MK-3682, which is currently in Phase III clinical trials for treating hepatitis C. This work was published recently in Science (Science, 2017, 356, 426-430.) and highlighted by C&EN (C&EN, 2017, 95, 5.) as well as X-MOL News.